[go: up one dir, main page]

EP2739636A1 - Oligosaccharides et conjugués d'oligosaccharides-protéines provenant de polysaccarides ps-i de clostridium difficile, leurs procédés de synthèse et d'utilisation, en particulier en tant que vaccins et outils de diagnostic - Google Patents

Oligosaccharides et conjugués d'oligosaccharides-protéines provenant de polysaccarides ps-i de clostridium difficile, leurs procédés de synthèse et d'utilisation, en particulier en tant que vaccins et outils de diagnostic

Info

Publication number
EP2739636A1
EP2739636A1 EP12740904.3A EP12740904A EP2739636A1 EP 2739636 A1 EP2739636 A1 EP 2739636A1 EP 12740904 A EP12740904 A EP 12740904A EP 2739636 A1 EP2739636 A1 EP 2739636A1
Authority
EP
European Patent Office
Prior art keywords
pentasaccharide
linker
mmol
building block
synthetic oligosaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP12740904.3A
Other languages
German (de)
English (en)
Other versions
EP2739636B1 (fr
Inventor
Peter H. Seeberger
Christopher E. Martin
Felix BROECKER
Chakkumkal ANISH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften
Priority to EP12740904.3A priority Critical patent/EP2739636B1/fr
Publication of EP2739636A1 publication Critical patent/EP2739636A1/fr
Application granted granted Critical
Publication of EP2739636B1 publication Critical patent/EP2739636B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/08—Deoxysugars; Unsaturated sugars; Osones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria

Definitions

  • Oligosaccharides and Oligosaccharide-protein conjugates derived from Clostridium difficile polysaccharide PS-I Oligosaccharides and Oligosaccharide-protein conjugates derived from Clostridium difficile polysaccharide PS-I
  • Clostridium difficile is a Gram-positive, spore forming anaerobic bacterium that colonizes the intestinal tract of humans thus leading to C. difficile infections (CDI) .
  • CDI has become the most commonly diagnosed cause of hospital-acquired diarrhea, particularly in the risk groups including elderly and immunodeficient patients as well as those receiving antibiotic treatment.
  • a steep rise in CDI incidents over the past decade is attributed to the emergence of the hypervirulent, and now predominant strain ribotype 27, causing epidemic outbreaks with increased morbidity, mortality and high relapse rates.
  • the costs to treat patients have greatly increased, particularly in the case of recurring CDI.
  • Preventive methods, such as vaccination of risk groups may be useful and cost-efficient means to avoid future infections.
  • vaccination against C. difficile should be economically feasible (B. Y. Lee et al., Vaccine, 2010, 28, 5245) a vaccine has not yet been developed.
  • Carbohydrates exposed on the cell-surface of pathogens are often immunogenic and constitute potential candidates for vaccine development.
  • carbohydrate antigen vaccines can elicit a long lasting T-cell dependent protection (C. Snapper and J. Mond, J. Immunol., 1996, 157, 2229).
  • Several vaccines containing carbohydrates, isolated from biological sources, are in routine use (G. Ada and D. Isaacs, Clin. Microbiol. Infect., 2003, 9, 79) .
  • Vaccines based on synthetic carbohydrate antigens against bacteria, viruses, parasites and cancer are currently in preclinical and clinical development (a) R. D. Astronomo and D. R.
  • the synthetic PS-II hapten is immunogenic when conjugated to a carrier protein and antibodies found in the stool of C. difficile patients bind to the synthetic PS-II hexasaccharide (Oberli et al., ibid.).
  • the pentasaccharide phosphate repeating unit PS-I was reported as [ ⁇ 4) - ⁇ -Rhap- (1 ⁇ 3) - ⁇ -Glcp- (1 ⁇ 4) - [ -Rhap- ( 1 ⁇ 3 ) ] - -Glcp- ( 1 ⁇ 2 ) -a- Glcp-(1 ⁇ P] and it is suggested to be specific for the strain ribotype 27.
  • a main object of the present invention is to provide novel and effective means to prevent and/or to treat C. difficile associated diseases, in particular related to the hypervirulent strain ribotype 027.
  • a further object is to provide novel and effective means to detect C. difficile in a sample and/or a C. difficile infection in a subject.
  • a further object is to provide novel and effective means to identify a certain strain of C. difficile in a sample and/or a C. difficile infected subject.
  • a further object is to provide novel and effective standards for immunoassays for the detection of C. difficile.
  • the present inventors succeeded in the first total synthesis of a pentasaccharide derived from the repeating unit of the C. difficile polysaccharide PS-I, and its conjugation to the diphtheria toxoid C rmig 7 .
  • the above main object of the invention is achieved by providing the synthetic oligosaccharide, in particular pentasaccharide, according to claim 1, the oligosaccharide-protein conjugate according to claim 7 and the composition according to claim 9. Further objects are achieved by providing the antibody of claim 11, the methods of detection and identification according to claims 18-19, and the methods of synthesis according to claims 15-17 and 26-27. Preferred embodiments and other aspects of the invention are the subject of further claims.
  • the present invention provides an oligosaccharide, in particular synthetic oligosaccharide, derived from the repeating unit of the Clostridium difficile glycopolymer PS-I and an oligosaccharide-protein conjugate comprising said oligosaccharide coupled to a protein carrier.
  • the oligosaccharide is the pentasaccharide having the sequence -L-Rhap- ( 1-3) - ⁇ -D-Glcp- (1- ) - [a-L-Rhap- d ⁇ 3] -oi- D-Glcp- (1 ⁇ 2) -a- D-Glcp or a (synthetic) fragment or derivative thereof.
  • derivative means generally any structurally related molecule having the same scaffold as the basic molecule but which is modified by the addition, deletion or substitution of one or more functional groups.
  • oligosaccharide derivative as used herein may be obtained by replacement of one or more of the hydroxyl groups by other functional groups or atoms or by introducing additional substituents such as linker groups.
  • fragment as used herein includes tetra-, tri-, di- and monosaccharides which are constituting units of the pentasaccharide having the sequence a-L-Rhap- ( 1 ⁇ 3 ) - ⁇ -D-Glcp- (1 ⁇ 4 ) - [oi-L-Rhap- ( 1 ⁇ 3] -a-D-Glcp- (1—2) -a-D-Glcp from above or from a derivative thereof, in particular a derivative comprising one or more linker group (s).
  • the oligosaccharide bears at least one linker for conjugation to a carrier protein or for immobilization a surface.
  • the linker or spacer group L may be any moiety that enables to couple the oligosaccharide to a carrier molecule or to the surface of a microarray.
  • linker groups A large variety of such linker groups are known in the art and a suitable linker group can be selected in dependence from the respective carrier molecule or surface group.
  • L may be an aliphatic or aromatic residue, e.g. an alkyl(en) group or phenyl (en) group, comprising a reactive functional group, such as an amino group, preferably a primary amino group, (activated) carboxy group, aldehyde, azide, alkenyl or alkinyl group.
  • L may comprise a polyether or polyester chain.
  • L is selected from the group comprising primary alkylamines, alkyl or aralkyl residues with a terminal aldehyde, azide, alkine or alkene group or (activated) carboxy group, and alkylaryl and aryl residues, e.g. phenyl residues, comprising a reactive amine, aldehyde or azide group, or (activated) carboxy group.
  • L is (CH 2 ) n H 2 , with n being an integer from 2 to 50, preferably 3 to 20 or 3 to 10, such as 4 to 8.
  • the carrier may be any carrier molecule known in the art, in particular in the field of vaccine development, e.g. as disclosed in Hecht et al., Curr. Opin. Chem. Biol. 13, 354- 359. (2009) . More specifically the carrier is a protein carrier selected from the group comprising diphtheria toxoid CRMi9 7 , tetanus toxoid (TT) , outer membrane protein (OMP) , bovine serum albumin, (BSA) , keyhole limpet hemocyanine (KLH) , diphtheria toxoid (DT) , cholera toxoid (CT) , recombinant Pseudomonas aeruginosa exotoxin A (rEPA) , Clostridium difficile toxin A (TcdA) , Clostridium difficile toxin B (TcdB) .
  • TT tetanus toxoid
  • OMP bo
  • the synthetic pentasaccharide derived from the repeating unit of C. difficile PS-I will induce an immunogenic and antigenic response in mice, livestock and human patients.
  • an aspect of the present invention relates to a vaccine against the pathogen Clostridium difficile comprising at least one of the group consisting of the synthetic oligosaccharide according to claim 1, the oligosaccharide- protein conjugate according to claim 7, or a conjugate of the oligosaccharide according to claim 1 or derivative thereof with a non-protein carrier molecule.
  • the oligosaccharide-protein conjugate or the oligosaccharide, in particular the pentasaccharide, of the invention may be advantageously used for preparing a pharmaceutical composition for the treatment or prevention of a disease caused by a pathogenic strain of Clostridium difficile.
  • they may be used in a method for the treatment or prevention of a disease caused by the pathogen Clostridium difficile .
  • they may be used as diagnostic tools for detecting Clostridium difficile or identifying a certain strain of Clostridium difficile in a sample and/or a Clostridium difficile infection in a subject.
  • Such a method may be, e.g.
  • a diagnostic method for Clostridium difficile infection comprising the use of the synthetic oligosaccharide of any one of claims 1-8 or a mixture thereof. They may for example be used as effective standards for immunoassays for the detection of C. difficile.
  • a further aspect of the invention relates to an antibody having specificity for an immunogenic determinant derived from or comprising the repeating unit of the Clostridium difficile glycopolymer PS-I. More specifically, the immunogenic determinant comprises or consists of the pentasaccharide of claim 1.
  • said antibody has been raised against a oligosaccharide-protein conjugate wherein the oligosaccharide is the pentasacharide 1 or a derivative thereof and the protein carrier is diphtheria toxoid CRMi 97 .
  • the antibody may be a polyclonal or monoclonal antibody and monoclonal antibodies can be readily prepared by standard methods of the art (e.g. Kohler and Milstein (1975), Nature, 495-497).
  • the present invention also provides very favourable and efficient methods for synthesizing the pentasaccharide and pentasaccharide-protein conjugates selectively and in high yields. These methods involve the use of one or more of molecules 2, 2 ⁇ 3, 4, 5, 20, 21, 22, 23, 24, 27, 29, 30, 30 ⁇ 31, 32, 32 ⁇
  • Retrosynthetic analysis of pentasaccharide 1. comprises assembling the monosaccharide building blocks 2 and 3 or 4 shown in Scheme 1 to yield the corresponding disaccharide 21 of Scheme 5, reacting the disaccharide 21 with building block 4 to form the trisaccharide 23 of Scheme 5, subjecting the trisaccharide 23 to a bis-glycosylation reaction with 2 molecules of building block 5 shown in Scheme 1 to yield the fully protected pentasaccharide 24 in Scheme 5 and finally, after deprotection, to yield pentasaccharide 1.
  • This method can be generalized for preparing other pentasaccharides having the sequence a-L-Rhap- ( 1 ⁇ 3 ) - ⁇ -D-Glcp- (1 ⁇ 4) - [a-L-Rhap- (1 ⁇ 3) ] -a-D-Glcp- (1 ⁇ 2) -a-D-Glcp-L according to claim 1 wherein the specific amino linker of compound 1 is replaced by any linker L, in particular any linker L as defined in claims 3 or .
  • This linker may also be present on a position (sugar moiety) different from the specific position (sugar moiety) indicated above.
  • the generalized method comprises assembling a monosaccharide building block 2 wherein the specific protected amino linker of building block 2 is replaced by a protected or unprotected linker L, in particular a linker L as defined in claim 3 or 4, and building blocks 3 or 4 shown in Scheme 1 to yield the corresponding disaccharide 21 N , reacting the disaccharide 21" with building block 4 to form the trisaccharide 23 , subjecting the trisaccharide 23 v to a bis-glycosylation reaction with 2 molecules of building block 5 shown in Scheme 1 to yield the fully protected pentasaccharide 24" in Scheme 5 and finally, after deprotection, to yield pentasaccharide 1 wherein the specific amino linker of pentasaccharide 1 is replaced by a different linker L, in particular a linker L as defined in claim 3 or 4.
  • the method for preparing the oligosaccharide-protein conjugate of the present invention typically comprises coupling the oligosaccharide of claim 2 bearing a linker or spacer group L, in particular wherein L is ( CH 2 ) nNH 2 , with n being an integer from 2 to 50, preferably from 3 to 20, with a protein carrier.
  • the protein carrier may be any carrier disclosed above and in one specific embodiment the protein carrier is CRMi 97 .
  • the present inventors developed very effective methods for synthesizing a pentasaccharide having the sequence a-L-Rhap- (1 ⁇ 3) - ⁇ -D-Glcp- (1 ⁇ 4) - [ -L-Rhap- (1 ⁇ 3) ] -a-D-Glcp- ( 1 ⁇ 2 ) -a-D-Glc/7-L that comprises the PS-I repeating unit but differs from the natural pentasaccharide by the linker L.
  • the oligosaccharide was designed to carry a primary amine at the reducing terminus via a linker to facilitate conjugation to a protein carrier and attachment to microarrays or other surfaces.
  • the pentasaccharide 1 - wherein the linker comprises the (CH 2 )5NH 2 group - can be assembled from the monosaccharide building blocks 2 and 3 or 4, and the monosaccharide building block 5 and these assembling steps are outlined in more detail below.
  • analogous assembling steps can be performed using an analogous building block 2 differing from building block 2 only by the presence of a different linker, in particular such as defined in claims 3 or 4, resulting in an analogous pentasaccharide l .
  • the 1,2-cis glycosidic linkages of the glucose residues A and B were installed early in the synthesis by employing the non- participating protecting groups 2-naphthylmethyl (NAP) and benzyl in 2-positions.
  • the temporary protecting groups Lev and Fmoc present in the glucose building blocks B and C were chosen for their compatibility with automated solid phase synthesis (K. R. Love and P. H. Seeberger, Angew. Chem. Int. Ed., 2004, 43, 602) . Both Rha residues D and D' were installed in a single bisglycosylation reaction.
  • Reagents and conditions a) NaH, NAPBr, DMF, 0 °C to rt, 92%; b) HO (CH 2 ) 5 NBnCbz, NIS, TfOH, toluene/dioxane, -40°C to -20°C; c) DDQ, DCM, H 2 0, 35% over 2 steps.
  • thioglucoside 11 that served as common precursor for building blocks 3 and 4 commenced from ⁇ -d- glucose pentaacetate 8 (Scheme 3) .
  • Use of the nontoxic and odorless 2-methyl-5- tert-butyl-thiophenol group ensured exclusive formation of ⁇ -anomer of thioglucoside 9 (M. Collot, J. Savreux and J.-M. Mallet, Tetrahedron, 2008, 64, 1523).
  • the acetyl groups were removed and the 4- and 6-hydroxyl groups of the resulting tetraol were regioselectively protected as a 4 , 6-O-benzylidene acetal (J. S. S. Rountree and P. V.
  • the assembly of the pentasaccharide target was achieved in seven linear steps by combining the monosaccharide building blocks in sequence (Scheme 5) .
  • the first synthesis of the C. difficile cell- surface PS-I pentasaccharide 1 was achieved employing a linear strategy that serves to scout reaction conditions for automated solid phase synthesis and to identify robust and efficient monosaccharide building blocks.
  • Four such building blocks 2-5 were prepared.
  • Glycosyl phosphate 4 proved a significantly better building block than identically protected thioglycoside 3.
  • the present inventors also developed an alternative route of synthesis based on a similar strategy as outlined above which is even more efficient and results in greatly improved yields of the PS-I pentasaccharide product.
  • Synthesis of the pentasaccharide 1 according to method B preferably comprises assembling the monosaccharide building blocks 2 and 27 shown in Scheme 8 to yield the corresponding disaccharide 30 of scheme 8, reacting the disaccharide 30 with building block 4 or 29 to form the protected trisaccharide 32 of scheme 8, deprotecting the trisaccharide 32 to obtain trisaccaride 33 and subjecting trisaccharide 33 to a bis- glycosylation reaction with 2 molecules of building block 5 shown in Scheme 8 to yield the fully protected pentasaccharide 34 in Scheme 8 and finally, after deprotection, to yield pentasaccharide 1.
  • Formation of the Glc(l- 4)Glc linkage proceeded in 92% yield, a huge improvement compared to 38% in method A.
  • This method can be generalized for preparing other pentasaccharides having the sequence a-L-Rhap- ( 1 ⁇ 3 ) - ⁇ - D-Glcp- (1 ⁇ 4) - [ oi-L-Rhap- (1 ⁇ 3) ] - - D-Glcp- (1 ⁇ 2) -a-D-Glcp-L according to claim 1 wherein the specific amino linker of compound 1 is replaced by any linker L, in particular any linker L as defined in claims 3 or .
  • This linker may also be present on a position (sugar moiety) different from the specific position (sugar moiety) indicated above.
  • the generalized method comprises assembling a monosaccharide building block 2 V , wherein the specific protected amino linker of building block 2 is replaced by a protected or unprotected linker L, in particular a linker L as defined in claim 3 or 4, and building block 27 shown in Scheme 8 to yield the corresponding disaccharide 30 reacting the disaccharide 30 s with building block 4 or 29 to form the corresponding protected trisaccharide 32 deprotecting the trisaccharide 32 x to obtain trisaccaride 33', subjecting the trisaccharide 33 % to a bis-glycosylation reaction with 2 molecules of building block 5 shown in Scheme 1 to yield the fully protected pentasaccharide 34 and finally, after deprotection, to yield pentasaccharide 1", wherein the specific amino linker of pentasaccharide 1 is replaced by a different linker L, in particular as defined in claim 3 or 4.
  • a comprehensive set of PS-I substructures 35-39 (Scheme 9) carrying an amino-linker was synthesized.
  • the pentasaccharide repeating unit 1 is built up from glucose residues A, B and C and terminal rhamnoses D and D' .
  • Disaccharide 35 contains A and B, trisaccharide 36 A, B and C.
  • the sequence BCD' is covered by trisaccharide 37.
  • Disaccharide 38 covers both the BD and CD' sequence.
  • Rhamnose substructure 39 represents D and D' .
  • Oligosaccharides 38 (Scheme 12) and 37 (Scheme 13) containing a terminal rhamnose residue were synthesized relying on disaccharide 41 which in its turn was obtained by union of 40 and 5.
  • Rhamnoside 39 (Scheme 14) bearing an anomeric linker was attained by combining 5 and 5-aminopentanol.
  • Microarray-chips containing 1 and the substructures 36-39 were prepared. This set of oligosaccharides substructures covalently linked to a surface was used to identify binding epitopes of anti PS-I pentasaccharide antibodies raised in mice ( Figure 6 ) .
  • the pentasaccharide 1 or 1 obtained as outlined above or a fragment or derivative thereof can be coupled to a carrier protein by a variety of known methods.
  • Oligosaccharides in particular pentasaccharide 1 and substructures 35 through 39, were immobilized on the surface of NHS-activated glass slides via their terminal primary amine group of the linker moiety. These microarrays were used to detect and quantify oligosaccharide-specific antibodies.
  • mABs Monoclonal antibodes
  • the invention is further illustrating by the following non- limiting Examples and Figures.
  • Glycoconj ugate 1 composed of hapten 1 (pentasaccharide 1) and protein CRMi 97 Figure 2. Characterization of glycoconj ugate la;
  • FIG. Microarray analysis of immune response against glycoconjugate. Dilutions of pooled sera in PBS are indicated under the microarray images.
  • Figure 7. Antibody titers against the PS-I pentasaccharide (left), CRM197 (center), and spacer moiety (right), as determined by microarray analysis Figure 8. Isotype analysis of the immune response against PS-I pentasaccharide
  • the pentasaccharide was designed to provide, by means of a linker group, a primary amine at the reducing terminus to facilitate conjugation to a protein carrier and attachment to microarrays and other surfaces.
  • the linker comprises the (CH 2 )s H2 group and the overall synthesis was performed according to scheme 5 or 8 above as indicated.
  • High-resolution mass spectra were recorded with an Agilent 6210 ESI-TOF mass spectrometer at the Freie Universitat Berlin, Mass Spectrometry Core Facility.
  • MALDI-TOF spectra were recorded on a Bruker Daltonics Autoflex Speed. Synthetic carbohydrates were measured using a 2,4,6- trihydroxyacetophenone (THAP) matrix, proteins and glycoconjugates were measured using 2 , 4-dihydroxyacetophenone (DHAP) as matrix.
  • THAP 2,4,6- trihydroxyacetophenone
  • DHAP 4-dihydroxyacetophenone
  • TLC thin layer chromatography
  • Kieselgel 60 F254 glass plates precoated with a 0.25 mm thickness of silica gel.
  • the TLC plates were visualized with UV light and by staining with Hanessian solution (eerie sulfate and ammonium molybdate in aqueous sulfuric acid) or a 1:1 mixture of H 2 S0 4 (2N) and resorcine monomethylether (0.2%) in ethanol.
  • Hanessian solution eerie sulfate and ammonium molybdate in aqueous sulfuric acid
  • 2N resorcine monomethylether
  • Column chromatography was performed using Kieselgel 60 (230-400 mesh) .
  • SEC-HPLC analyses were performed on a TSKgel-G4000S XL column connected to an Agilent 1200 HPLC system equipped with a PDA detector.
  • Elution buffer was constituted by lOOmM sodium phosphate pH 7.2, 100 mM NaCl flow rate was 0.4 mL/min.
  • SDS PAGE gels were run with 10 % SDS PAGE gel in reducing conditions at 130 V and 50 mA, molecular weight marker (Invitrogen bench marker) was used.
  • Tetrol SI (1.0 g) was dissolved in anhydrous acetonitrile (11.3 mL) at RT under argon atmosphere and benzaldehyde dimethylacetal (880 pL, 5.84 mmol, 2 eq) and camphorsulfonic acid (7 mg, 0.029 mmol, 0.01 eq) were added. After 2.5 h (TLC: cyclohexane/ethyl acetate, 1:2), the reaction was quenched with triethylamine, and the solvents were evaporated in vacuo to give 1.5 g of colorless oil.
  • Thioglucoside 17 (690 mg, 0.91 mmol) was coevaporated with toluene three times and dried in vacuo, then dissolved in anhydrous DCM (10 ml). Freshly activated molecular sieves (4 A) and dibutyl hydrogen phosphate (542 ⁇ , 2.73 mmol) were added and the solution cooled to 0 °C. NIS (246 mg, 1.09 mmol), followed by TfOH (10 ⁇ , 0.11 mmol) was added and stirred at 0 °C for one hour. The reaction was quenched by the addition of pyridine, diluted with DCM and washed with aqueous Na 2 S 2 0 3 and saturated aqueous NaHC0 3 solutions.
  • Rhamnoside 18 (500 mg, 1.39 mmol) was dissolved in a solution of DCM (1 ml) and pyridine (1 ml).
  • DMAP (68 mg, 0.56 mmol) was added and the mixture cooled to 0 °C, then BzCl (780 mg, 5.56 mmol) was added and the reaction warmed to room temperature over night.
  • the reaction was quenched with MeOH, diluted with DCM and the organic layer was washed with a 0.01 M HC1 solution and saturated aqueous NaHC0 3 solution. The organic layer was dried over MgSO ⁇ and concentrated.
  • Glucoside donor 3 (326 mg, 0.34 mmol) and glucoside acceptor 2 (262 mg, 0.35 mmol) were coevaporated with toluene three times and dried in vacuo.
  • the mixture was dissolved in anhydrous Et 2 0 (3 ml), NIS (93 mg, 0.41 mmol) was added and cooled to -35°C.
  • TfOH (3.7 ⁇ , 41 ⁇ ) was added and the mixture was stirred and warmed up to -10 °C in one hour.
  • the reaction was quenched by the addition of pyridine, diluted with DCM and washed with aqueous Na 2 S 2 C>3 and saturated aqueous NaHC0 3 solutions.
  • the crude product was dissolved in DMF (2.5 ml), and treated with a solution of TBAF' 3H 2 0 (137 mg, 0.43 mmol) and AcOH (29 ⁇ , 0.51 mmol) in DMF (2.5 ml) at 50°C for three days. After dilution with Et 2 0 the phases were separated and the organic phase washed with a 0.1 M HCl solution, saturated aqueous NaHC0 3 solution and brine. The organic phase was then dried over MgS04, filtered and concentrated. The crude product was purified by column chromatography on silica gel (toluene/acetone) to afford 33 (52 mg, 0.03 mmol, 68%).
  • Disaccharide 41 (144 mg, 0.13 mmol) and glucoside 44 (102 mg, 0.12 mmol) were coevaporated with toluene three times and dried in vacuo.
  • the mixture was dissolved in DCM (4 ml) and NIS (36 mg, 0.16 mmol) was added and cooled to -20 °C.
  • TfOH (1.4 ⁇ , 16 ⁇ ) was added and the mixture was stirred and warmed up to 0 °C in two hours.
  • the reaction was quenched by the addition of aqueous Na 2 S 2 0 3 and saturated aqueous NaHC0 3 .
  • the phases were separated and the aqueous phase was extracted with DCM.
  • the combined organic phases were dried over MgS0 4 , filtered and concentrated.
  • Polysaccharide vaccines provoke exclusively a T-cell independent immune response and do not induce an immunoglobulin class switch.
  • the synthetic repeating unit 1 of the Clostridium difficile glycopolymer PS-I was conjugated to the protein carrier Crmi 97 .
  • the detoxified diphtheria toxoid Crmi 97 was chosen as a carrier since it is an approved constituent of licensed vaccines (Barocchi et al. (2007), Vaccine 25, 2963-73) .
  • the oligosaccharide/CRMi 97 ratio was determined by MALDI-TOF MS.
  • the mass analysis of CRMi 97 yielded a m/z ion at 58.2 kDa.
  • the mass analysis of the conjugate yielded a major m/z ion at 67.7 kDa and further peaks -1000 Da apart, corresponding to conjugates of different valencies ( Figure 4b) .
  • An average of 9.6 PS-I pentasaccharide 1 molecules were loaded on one CRMi 9 protein, resulting in conjugate lb.
  • the carbohydrate content was calculated to 300 ⁇ 46 ⁇ g/mL (mean ⁇ SD) and verified by colorimetric anthrone assay (302 ⁇ 76 ⁇ g mL) , an approved method for the carbohydrate determination of the licensed pneumococcal conjugate vaccine Prevenar (Pfizer) .
  • Pentasaccharide l-CRMi 97 conjugate and unconjugated CRMi 97 were dissolved in Lammli buffer (0.125 M Tris, 20% (v/v) glycerol, 4% (w/v) SDS, 5% (v/v) beta-mercaptoethanol , bromophenol, pH 6.8) and boiled at 95°C for 5 minutes. Samples were run in 10% polyacrylamide gels and stained with 0.025% (w/v) Coomassie Brilliant blue R-250 in an aqueous solution containing 40% (v/v) methanol and 7% (v/v) acetic acid.
  • Anthrone assays were performed in 96-well format in a modified assay according to Leyva et al., Biologicals 36:134-141, 2008. Briefly, 75 L of anthrone reagent (0.1% (w/v) in concentrated sulfuric acid) was added to each well of a 96-well microtiter plate containing 25 yL of standard solutions, sample dilutions and blank. Plates were first placed at 4°C for 10 minutes, then incubated at 100°C for 20 minutes, and cooled down at room temperature for 20 minutes. Absorbance at 579 nm was determined in a microplate reader. Colorimetric response was compared to a standard curve based on glucose and rhamnose in a 3:2 molar ratio.
  • PS-I pentasaccharide 1 in three different concentrations (1, 0.5 and 0.1 mM) , CRM197 (1, 0.5 and 0.1 ⁇ ) and bovine serum albumin (BSA) -spacer-GlcNAc conjugate (1, 0.5 and 0.1 ⁇ ) were spotted in triplicate onto the surface of the microarray slides (N-hydroxysuccinimid ester-activated glass slides (CodeLink) ) as shown in Figure 5.
  • BSA-spacer-GlcNAc was used to assess immunogenicity against the spacer moiety of the conjugate.
  • phosphate-buffer saline PBS
  • two unrelated oligosaccharides both at a concentration of 1 mM
  • Microarrays were designed such that high-throughput analysis of 64 samples per array was possible.
  • IgG antibody responses were quantified by determination of the fluorescence intensity values using the sera of individual mice. While the conjugate already showed immunogenicity without adjuvant ( Figure 7, left diagram, white bars), IgG titers against PS-I pentasaccharide were markedly increased when Freund's adjuvant was used (light grey bars), and, more pronounced, with Alum adjuvant (dark grey bars) .
  • IgG antibody titers against the carrier protein CRMi 97 were lower in mice immunized without adjuvant than in mice immunized with Freund's and Alum adjuvant (Figure 7, central diagram). There was no IgG response against the spacer moiety in mice immunized without adjuvant, but in mice immunized with Freund's and Alum adjuvants ( Figure 7, right diagram).
  • mice immunized with Freund' s adjuvant show a relatively high proportion of antibodies of the IgG2a and IgG3 subclasses in addition to IgGl.
  • IgG3 and IgG2a are mainly induced by T-cell independent antigens such as polysaccharides, while IgGl is mainly T-cell dependent and directed against protein antigens.
  • microarray slides with substructures 35-39 in addition to 1 were prepared ( Figure 9) .
  • CRMi 97 , BSA-spacer-GlcNAc were included as well as two unrelated oligosaccharides and PBS as negative controls. This array was used to assess immune responses in pooled sera of the three groups of mice immunized with conjugate.
  • Figure 11 shows the deletion sequence analysis of the immune response of mice immunized with glycoconjugate and Freund' s adjuvant .
  • FIG. 11 shows the deletion sequence analysis of the immune response of mice immunized with glycoconjugate and Alum adjuvant.
  • mice immunized without adjuvant or with Freund' s adjuvant contain antibodies against substructure with rhamnose, while the IgG responses against disaccharide 38 is generally higher than those against trisaccharide 37, albeit 37 is closer to the original PS-I pentasaccharide antigen 1 used for immunization.
  • the IgG antibody response in mice immunized with Alum adjuvant shows a more specific reactivity against the PS-I pentasaccharide with lower titers against deletion sequences 38 and 37 ( Figure 12) . No antibody response against oligoglucose disaccharide 35 nor trisaccharide 36 was detected in any of the groups.
  • Disaccharide 38 may be the minimal epitope of the PS-I pentasaccharide .
  • Monoclonal antibodies were generated with the traditional hybridoma technique [Kohler and Milstein, 1975] .
  • Figure 13 shows different monoclonal antibodies against PS-I.
  • One mouse of the Alum group was subjected to a second boosting immunization (s.c.) at week 5 and three final boostings (intraperitoneal, i.p.) at three consecutive days in week 7.
  • mice One day after final boosting, the mouse was sacrificed, the spleen was removed and subjected to monoclonal antibody development. After three rounds of subcloning, supernatants of three monoclonal antibodies (mAB) -producing clones, 2C5, 10A1 and 10D6, were subjected to isotype analysis as in Figure 8, using hybridoma supernatants in a 1:3125 dilution.
  • mAB monoclonal antibodies
  • mice Six to eight-weeks old female C57BL/6 mice were immunized s.c. with conjugate corresponding to 3 ⁇ g PS-I pentasaccharide 1 with Freund' s (priming immunizations with Freund' s Complete Adjuvant, boosting immunizations with Freund' s Incomplete Adjuvant, both Sigma) or Aluminium Hydroxide Gel Adjuvant (Brenntag Biosector, Frederikssund, Denmark) , or without adjuvant. Mice received boosting injections after 2 weeks. For all immunizations, antigen was diluted in sterile PBS to a total injection volume of 100 ⁇ , per mouse.
  • One mouse of the Alum group received a second boosting injection s.c. at week 5 after first immunization, and, prior to being sacrificed, three final boosting injections via the intraperitoneal (i.p.) route, on three consecutive days at week 7.
  • Oligosaccharides bearing an amine linker, or proteins were dissolved in sodium phosphate buffer (50 mM, pH 8.5) and printed robotically using a piezoelectric spotting device (Sll, Scienion, Berlin, Germany) onto NHS-activated glass slides (CodeLink) . Slides were incubated in a humid chamber to complete reaction for 24 hours and stored in an anhydrous environment. Prior to the experiment, remaining succinimidyl groups were quenched by incubating slides in 100 mM ethanolamine in sodium phosphate buffer (pH 9, 50 mM) for 1 hour at 50°C. Slides were rinsed three times with deionized water and dried by centrifugation . Microarray binding assays
  • slides were incubated with fluorescence-labeled detection antibody diluted in 1% BSA in PBS (w/v) for 1 hour at room temperature in a humid chamber. Slides were washed three times with PBS-Tween-20 (0.1% v/v) and rinsed once with deionized water and dried by centrifugation . Slides were scanned with a GenePix 4300A scanner (Molecular Devices) using the GenePix Pro 7 software.
  • Detection antibodies used were Anti-Mouse IgG (whole molecule) -FITC (Sigma), Alexa Fluor 635 Goat Anti-Mouse IgG (H+L) (Life Technologies) and Alexa Fluor 594 Goat Anti-Mouse IgGl ( ⁇ ) (Life Technologies) in 1:400 dilutions, as well as Alexa Fluor 647 Goat Anti-Mouse IgG2a (y2a ) and Alexa Fluor 488
  • mABs Monoclonal antibodes
  • spleenocytes of one mouse were fused with 10 8 mouse myeloma cells in the presence of 50% PEG 1500. Fused cells were selected with complete growth medium (IMDM supplemented with 10% heat- inactivated fetal calf serum, 2 mM L-glutamine, 24 ⁇ beta- mercaptoethanol, 100 ⁇ hypoxanthine, 16 ⁇ thymidine, nonessential amino acids, 100 U/mL penicillin, 100 ⁇ g/mL streptomycin, 50 ⁇ g/mL gentamycin, 10% hybridoma cloning supplement (BM Condimed HI, Roche)) with 0.4 ⁇ aminopterin.
  • IMDM complete growth medium
  • IMDM heat- inactivated fetal calf serum
  • 2 mM L-glutamine 24 ⁇ beta- mercaptoethanol
  • 100 ⁇ hypoxanthine 16 ⁇ thymidine
  • Hybridoma cells were maintained at 37 °C at 5% C0 2 .
  • Hybridoma cells were subjected to three consecutive subcloning steps by limited dilution. Clones producing antibodies against PS-I pentasaccharide were identified by microarray analysis.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un oligosaccharide synthétique représentant une partie de l'unité de répétition d'un glycopolymère PS-I de Clostridie difficile et comprenant la séquence du pentasaccharide a-L-Rhap-(1→3)-β-D-Glcp-(1→4) -[a-L-Rhap-(1→3]-a-D-Glcp-(1→2)-a-D-Glcp ou un fragment ou un dérivé synthétique de celui-ci. L'oligosaccharide synthétique porte, de préférence, un lieur L pour conjugaison avec une protéine porteuse ou pour immobilisation sur une surface. Selon d'autres aspects, l'invention concerne des méthodes avantageuses pour effectuer la synthèse de l'oligosaccharide synthétique et du conjugué d'oligosaccharide-protéine ainsi que leurs utilisations, en particulier en tant que vaccins et outils de diagnostic.
EP12740904.3A 2011-08-02 2012-07-30 Oligosaccharides et conjugués protéine-oligosaccharides dérivés de ps-i de polysaccharide clostridium difficile, procédés de synthèse et utilisations associées, en particulier en tant que vaccins et outils de diagnostic Not-in-force EP2739636B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12740904.3A EP2739636B1 (fr) 2011-08-02 2012-07-30 Oligosaccharides et conjugués protéine-oligosaccharides dérivés de ps-i de polysaccharide clostridium difficile, procédés de synthèse et utilisations associées, en particulier en tant que vaccins et outils de diagnostic

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161514095P 2011-08-02 2011-08-02
EP11006355A EP2554549A1 (fr) 2011-08-02 2011-08-02 Oligosaccharides et conjugués de protéine d'oligosaccharides dérivés de PS-I de polysaccharide difficile de Clostridium, procédés de synthèse et utilisations associées, en particulier en tant que vaccins et outils de diagnostic
PCT/EP2012/003240 WO2013017254A1 (fr) 2011-08-02 2012-07-30 Oligosaccharides et conjugués d'oligosaccharides-protéines provenant de polysaccarides ps-i de clostridium difficile, leurs procédés de synthèse et d'utilisation, en particulier en tant que vaccins et outils de diagnostic
EP12740904.3A EP2739636B1 (fr) 2011-08-02 2012-07-30 Oligosaccharides et conjugués protéine-oligosaccharides dérivés de ps-i de polysaccharide clostridium difficile, procédés de synthèse et utilisations associées, en particulier en tant que vaccins et outils de diagnostic

Publications (2)

Publication Number Publication Date
EP2739636A1 true EP2739636A1 (fr) 2014-06-11
EP2739636B1 EP2739636B1 (fr) 2018-09-26

Family

ID=44583912

Family Applications (2)

Application Number Title Priority Date Filing Date
EP11006355A Withdrawn EP2554549A1 (fr) 2011-08-02 2011-08-02 Oligosaccharides et conjugués de protéine d'oligosaccharides dérivés de PS-I de polysaccharide difficile de Clostridium, procédés de synthèse et utilisations associées, en particulier en tant que vaccins et outils de diagnostic
EP12740904.3A Not-in-force EP2739636B1 (fr) 2011-08-02 2012-07-30 Oligosaccharides et conjugués protéine-oligosaccharides dérivés de ps-i de polysaccharide clostridium difficile, procédés de synthèse et utilisations associées, en particulier en tant que vaccins et outils de diagnostic

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP11006355A Withdrawn EP2554549A1 (fr) 2011-08-02 2011-08-02 Oligosaccharides et conjugués de protéine d'oligosaccharides dérivés de PS-I de polysaccharide difficile de Clostridium, procédés de synthèse et utilisations associées, en particulier en tant que vaccins et outils de diagnostic

Country Status (5)

Country Link
US (1) US9238669B2 (fr)
EP (2) EP2554549A1 (fr)
AU (1) AU2012292430B2 (fr)
CA (1) CA2843908C (fr)
WO (1) WO2013017254A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015002954A1 (fr) * 2013-07-03 2015-01-08 Synglyco Pharmaceuticals, Inc. Oligosaccharides de synthèse pour vaccin contre p. aeruginosa
DK3174553T3 (en) * 2014-07-25 2018-07-23 Biosynth Srl GLYCOCOONJUGATE VACCINES INCLUDING BASIC UNITS OF A MOLECULE CONSTRUCTION THAT EXPRESSES MULTIPLE INTEGRATED EPITOPES FOR THE FORMULATION OF A WIDE-SPECTED VACCINE AGAINST INFECTIONS BASED ON BACTEROGEN
EP3274358B1 (fr) * 2015-03-27 2020-09-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccin contre klebsellia pneumoniae resistante aux carbapénèmes
EP3492481A1 (fr) * 2017-11-30 2019-06-05 Vaxxilon AG Vaccin contre klebsiella pneumoniae
CN109668873B (zh) * 2018-12-05 2021-03-16 山东恒业生物技术有限公司 一种活载体疫苗活性检测装置及其使用方法
CN110128491B (zh) * 2019-05-16 2022-07-22 山东大学 一种牛樟芝半乳甘露寡糖苷衍生物及其制备方法与应用
CN119219713B (zh) * 2023-06-28 2025-10-17 山东大学 一种具有抗肿瘤活性的半乳甘露四糖及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07109286A (ja) * 1993-10-12 1995-04-25 Mect Corp ネオヘスペリドース誘導体
CA2698157C (fr) * 2007-09-11 2016-10-11 University Of Guelph Nouveaux polysaccharides immunogenes issus de clostridium difficile

Also Published As

Publication number Publication date
US9238669B2 (en) 2016-01-19
US20140193416A1 (en) 2014-07-10
AU2012292430B2 (en) 2017-06-01
EP2554549A1 (fr) 2013-02-06
CA2843908A1 (fr) 2013-02-07
CA2843908C (fr) 2019-06-11
EP2739636B1 (fr) 2018-09-26
AU2012292430A1 (en) 2014-03-13
WO2013017254A1 (fr) 2013-02-07

Similar Documents

Publication Publication Date Title
AU2012292430B2 (en) Oligosaccharides and oligosaccharide-protein conjugates derived from Clostridium difficile polysaccaride PS-I, methods of synthesis and uses thereof, in particular as vaccines and diagnostic tools
US20130243751A1 (en) Glycoconjugates and their use as potential vaccines against infection by shigella flexneri
US9815889B2 (en) Antibodies for prevention and treatment of diseases caused by clostridium difficile
Harale et al. Synthesis of a tetrasaccharide and its glycoconjugate corresponding to the capsular polysaccharide of Neisseria meningitidis serogroup X and its immunochemical studies
Jiao et al. Clostridium difficile PSI polysaccharide: synthesis of pentasaccharide repeating block, conjugation to exotoxin B subunit, and detection of natural anti-PSI IgG antibodies in horse serum
Cloutier et al. Melioidosis patient serum-reactive synthetic tetrasaccharides bearing the predominant epitopes of Burkholderia pseudomallei and Burkholderia mallei O-antigens
US10087242B2 (en) Glycoconjugates and use thereof as vaccine against Shigella flexneri serotype 3a and X
Shang et al. Chemical synthesis of the outer core oligosaccharide of Escherichia coli R3 and immunological evaluation
Zhang et al. Total synthesis of the tetrasaccharide haptens of Vibrio vulnificus MO6-24 and BO62316 and immunological evaluation of their protein conjugates
Lipinski et al. A structurally diversified linker enhances the immune response to a small carbohydrate hapten
Zhang et al. Chemical synthesis and biological evaluation of penta-to octa-saccharide fragments of Vi polysaccharide from Salmonella typhi
CA3004305C (fr) Constructions d'antigenes synthetiques contre campylobacter jejuni
US12324832B2 (en) Application of heptoglycan-chain-containing oligosaccharide compounds in preparation of vaccine against Helicobacter pylori
Fusari et al. Synthesis of di-and tri-saccharide fragments of Salmonella typhi Vi capsular polysaccharide and their zwitterionic analogues
US7943594B2 (en) Solid-phase and solution-phase synthesis of glycosylphosphatidylinositol glycans
WO2014170681A9 (fr) Conjugués d'oligosaccharide et procédés d'utilisation
EP2911698B1 (fr) Glycoconjugués et leur utilisation comme vaccins potentiels contre une infection provoquée par des bactéries shigella flexneri
Milhomme et al. Synthesis and immunochemical evaluation of a non-methylated disaccharide analogue of the anthrax tetrasaccharide
Milhomme et al. Synthetic efforts towards glycoconjugate-based vaccines active against Anthrax
Keith Total Synthesis of the Morganella Morganii Zwitterionic Polysaccharide Repeating Unit
Sella Chemical synthesis of oligosaccharide antigens as vaccine candidates for Streptococcus suis serotypes 2 and 14
Xu Synthetic oligosaccharides as tools to investigate bacterial capsular polysaccharides and teichoic acids
Nishat Syntheses and immunological evaluation of zwitterionic polysaccharide (PS A1) based vaccines
Yu Chemical Synthesis of Outer Core Oligosaccharide of Escherichia Coli R3 and Convergent Synthesis of O-glycan Library
Serotypes Two Kdo-Heptose Regions Identified in

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140129

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20150701

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 1/12 20060101ALI20180515BHEP

Ipc: C07H 13/08 20060101ALI20180515BHEP

Ipc: C07H 5/04 20060101ALI20180515BHEP

Ipc: C07H 3/06 20060101AFI20180515BHEP

Ipc: C07H 15/20 20060101ALI20180515BHEP

Ipc: A61P 31/04 20060101ALI20180515BHEP

Ipc: C07K 16/12 20060101ALI20180515BHEP

Ipc: G01N 33/569 20060101ALI20180515BHEP

Ipc: C07H 3/08 20060101ALI20180515BHEP

Ipc: C07H 15/04 20060101ALI20180515BHEP

Ipc: A61K 31/7032 20060101ALI20180515BHEP

INTG Intention to grant announced

Effective date: 20180612

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1045917

Country of ref document: AT

Kind code of ref document: T

Effective date: 20181015

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012051519

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180926

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181227

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1045917

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180926

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190126

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190126

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012051519

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20190627

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190730

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190730

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20200722

Year of fee payment: 9

Ref country code: GB

Payment date: 20200728

Year of fee payment: 9

Ref country code: DE

Payment date: 20200701

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20200728

Year of fee payment: 9

Ref country code: BE

Payment date: 20200722

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20120730

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602012051519

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20210730

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20210731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210731

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210730

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220201

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210731